Resveratrol protects against a model of vacuous chewing movements induced by reserpine in mice

Behavioural Pharmacology

Volumn 22, Issue 1, 2011, Pages 71-75

  Busanello, Alcindo ^b   Barbosa, Nilda Berenice Vargas ^b   Peroza, Luis Ricardo ^a   Farias, Luana Echeverria ^a   Burger, Marilise Escobar ^a   Barreto, Katia Padilha ^a   Fachinetto, Roselei ^a  

^a Programa de Pós Graduação em Farmacologia   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Mouse; Neurodegenerative disease; Open field test; Orofacial dyskinesia; Parkinsonism

Indexed keywords

RESERPINE; RESVERATROL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXPLORATORY BEHAVIOR; LOCOMOTION; MASTICATION; MOUSE; NEUROPROTECTION; NONHUMAN; OPEN FIELD BEHAVIOR; OROFACIAL DYSKINESIA; PARKINSONISM; TREMOR;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DYSKINESIA, DRUG-INDUCED; MASTICATION; MICE; MOTOR ACTIVITY; RESERPINE; STILBENES;

EID: 78651394604     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e328341e9b4     Document Type: Article

References (54)

1. Abílio VC, Vera JAR Jr, Ferreira LSM, Duarte CRM, Carvalho RC, Grassl C, et al. (2002). Effects of melatonin on orofacial movements in rats. Psychopharmacology 161:340-347.
2. Aguiar AS Jr, Araújo AL, da-Cunha TR, Speck AE, Ignácio ZM, De-Mello N, et al. (2009). Physical exercise improves motor and short-term social memory deficits in reserpinized rats. Brain Res Bull 79:452-457.
3. Ahmad M, Saleem S, Ahmad AS, Yousuf S, Ansari MA, Khan MB, et al. (2005). Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine- induced parkinsonism in rats: neurobehavioral, neurochemical and immunohistochemical evidences. J Neurochem 93:94-104.
4. Anekonda TS (2006). Resveratrol-a boon for treating Alzheimer's disease? Brain Res Rev 52:316-326.
5. Andreassen OA, Jorgensen HA (2000). Neurotoxicity associated with neuroleptic- induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol 61:525-541.
6. Andreassen OA, Ferrante RJ, Aamo TO, Beal MF, Jorgensen HA (2003). Oral dyskinesias and histopathological alterations in substantia nigra after longterm haloperidol treatment of old rats. Neuroscience 122:717-725.
7. Baur JA, Sinclair DA (2006). Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5:493-506.
8. Bilska A, Dubiel M (2007). Alpha-lipoic acid differently affects the reserpineinduced oxidative stress in the striatum and prefrontal cortex of rat brain. Neuroscience 146:1758-1771.
9. Bove J, Prou D, Perier C, Przedborski S (2005). Toxin-induced models of Parkinson's disease. NeuroRx 2:484-494.
10. Broadhurst PL (1960). Experiments in psychogenetics. In: Eysenk HJ, editor. Experiments in personality. London: Routledge & Kegan Paul. pp. 76.
11. Burger ME, Audrei A, Callegari L, Athayde FR, Nogueira CW, Zeni G, et al. (2003). Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum. Prog Neuropsychopharmacol Biol Psychiatry 27:135-140.
12. Burger ME, Fachineto R, Alves A, Callegari L, Rocha JBT (2005). Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats. Brain Res 1031:202-210.
13. Burt D, Creese I, Snyder SH (1977). Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 196:326-327.
14. Castro JPMV, Frussa-Filho R, Fukushiro DF, Silva RH, MedranoWA, Ribeiro R de A, et al. (2006). Effects of baclofen on reserpine-induced vacuous chewing movements in mice. Brain Res Bull 68:436-441.
15. Colpo G, Trevisol F, Teixeira AM, Fachinetto R, Pereira RP, Athayde ML, et al. (2007). Ilex paraguariensis has antioxidant potential and attenuates haloperidol-induced orofacial dyskinesia and memory dysfunction in rats. Neurotox Res 12:171-180.
16. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux JL (2010). Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 54:7-16.
17. Coyle JT, Puttfarcken P (1993). Oxidative stress, glutamate, and neurodegenerative disorders. Science 262:689-695.
18. Dauer W, Przedborski S (2003). Parkinson's disease: mechanisms and models. Neuron 39:889-909.
19. Fachinetto R, Burger MB, Wagner C, Wondracek DC, Brito VB, Nogueira CW, et al. (2005). High fat diet increases the incidence of orofacial dyskinesia and oxidative stress in specific brain regions of rats. Pharmacol Biochem Behav 81:585-592.
20. Fachinetto R, Villarinho JG, Wagner C, Pereira RP, Puntel RL, Paixão MW, et al. (2007a). Diphenyl diselenide decreases the prevalence of vacuous chewing movements induced by fluphenazine in rats. Psychopharmacology 194:423-432.
21. Fachinetto R, Villarinho JG, Wagner C, Pereira RP, Ávila DS, Burger ME, et al. (2007b). Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter. Prog Neuropsychopharmacol Biol Psychiatry 31:1478-1486.
22. Faria RR, Abílio VC, Grassl C, Chinen CC, Ribeiro LT, Castro JPMV, et al. (2005). Beneficial effects of vitamin C and vitamin E on reserpine-induced oral dyskinesia in rats: critical role of striatal catalase activity. Neuropharmacology 48:993-1001.
23. Gé linas S, Martinoli M (2002). Neuroprotective effect of estradiol and phytoestrogens on MPP+ -induced cytotoxicity in neuronal PC12 cells. J Neurosci Res 70:90-96.
24. Hall ED, Vaishnav RA, Mustafá AG (2010). Antioxidant therapies for traumatic brain injury. Neurotherapeutics 7:51-61.
25. Ishrat T, Hoda MN, Khan MB, Yousuf S, Ahmad M, Khan MM, et al. (2009). Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT). Eur Neuropsychopharmacol 19:636-647.
26. Jenner P (2003). Oxidative stress in Parkinson's disease. Ann Neurol 53: S26-S36.
27. Jicha GA, Salamone JD (1991). Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletion: possible relation to Parkinsonian symptoms. J Neurosci 11:3822-3829.
28. Jin F,Wu Q, Lu YF, Gong QH, Shi JS (2008). Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur J Pharmacol 600: 78-82.
29. Kane JM, Smith JM (1982). Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 39:473-481.
30. Kelley AE, Bakshi VP, Delfs JM, Lang CG (1989). Cholinergic stimulation of the ventrolateral striatum elicits mouth movements in rats: pharmacological and regional specificity. Psychopharmacology 99:542-549.
31. Khan MM, Ahmad A, Ishrat T, Khan MB, Hoda MD, Khuwaja G, et al. (2010). Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Res 1328:139-151.
32. Kim J, Lee HJ, Lee KW (2010). Naturally occurring phytochemicals for the prevention of Alzheimer's disease. J Neurochem 112:1415-1430.
33. Kumar P, Padi SS, Naidu PS, Kumar A (2006). Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioral changes: possible neuroprotective mechanisms. Behav Pharmacol 17:485-492.
34. Liu XK, Wang G, Chen SD (2010). Modulation of the activity of dopaminergic neurons by SK channels: a potential target for the treatment of Parkinson's disease? Neurosci Bull 26:265-271.
35. Lohr JB, Kuczenski R, Niculescu AB (2003). Oxidative mechanisms and Tardive dyskinesia. CNS Drugs 17:47-62.
36. Luo L, Huang YM (2006). Effect of resveratrol on the cognitive ability of Alzheimeros mice. Zhong Nan Da Xue Xue Bao Yi Xue Ban 31:566-569.
37. Naidu PS, Singh A, Kulkarni SK (2004). Reversal of reserpine-induced orofacial dyskinesia and cognitive dysfunction by quercetin. Pharmacology 70: 59-67.
38. Naidu PS, Singh A, Kulkarni SK (2006). Effect of Withania somnifera root extract on reserpine-induced orofacial dyskinesia and cognitive dysfunction. Phytother Res 20:140-146.
39. Neisewander JL, Lucki I, Mcgonigle P (1991). Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment. Brain Res 558:27-35.
40. Neisewander JL, Castañeda E, Davis DA (1994). Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: support for a model of tardive dyskinesia. Psychopharmacology 116:79-84.
41. Pervaiz S, Holme AL (2009). Resveratrol: its biological targets and functional activity. Antioxid Redox Signal 11:2851-2897.
42. Ramassamy C (2006). Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol 545:51-64.
43. Salamone JD, Baskin P (1996). Vacuous jaw movements induced by acute reserpine and low-dose apomorphine: possible mode of Parkinsonian tremor. Pharmacol Biochem Behav 53:179-183.
44. Salamone JD, Mayorga AJ, Trevitt JT, Cousins MS, Conlan A, Nawab A (1998). Tremulous jaw movements in rats: a model of Parkinsonian tremor. Progress Neurobiol 56:591-611.
45. Salamone JD, Ishiwari K, Betz AJ, Farrar AM, Mingote SM, Font L, et al. (2008). Dopamine/adenosine interactions related to locomotion and tremor in animal models: possible relevance to parkinsonism. Parkinsonism Relat Disord 2:S130-S134.
46. Sun AY,Wang Q, Simonyi A, Sun GY (2010). Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol Neurobiol 41:375-383.
47. Vingtdeux V, Dreses-Werringloer U, Zhao H, Davies P, Marambaud P (2008). Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neuroscience 9:S6.
48. Wagner C, Vargas AP, Roos DH, Morel AF, Farina M, Nogueira CW, et al. (2010). Comparative study of quercetin and its two glycoside derivatives quercitrin and rutin against methylmercury (MeHg)-induced ROS production in rat brain slices. Arch Toxicol 84:89-97.
49. Woerner MG, Kane JM, Lieberman JA, Alvir J, Bergmann KJ, Borenstein M, et al. (1991). The prevalence of Tardive dyskinesia. J Clin Psychopharmacol 11:34-42.
50. Xu Y,Wang Z, You W, Zhang X, Li S, Barish PA, et al. (2010). Antidepressant-like effect of trans-resveratrol: involvement of serotonin and noradrenaline system. Eur Neuropsychopharmacol 20:405-413.
51. Yáñ ez M, Fraiz N, Cano E, Orallo F (2006). Inhibitory effects of cis- and transresveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochem Biophys Res Commun 344:688-695.
52. Yokoyama H, Kasai N, Ueda Y, Niwa R, Konaka R, Mori N, et al. (1998). In vivo analysis of hydrogen peroxide and lipid radicals in the striatum of rats under long-term administration of a neuroleptic. Free Radic Biol Med 24:1056-1060.
53. Yousuf S, Atif F, Ahmad M, Hoda N, Ishrat T, Khan B, Islam F (2009). Resveratrol exerts its neuroprotective effect by modulating mitochondrial dysfunctions and associated cell death during cerebral ischemia. Brain Res 1250:242-253.
54. Zafar KS, Sayeed I, Siddiqui A, Ahmad M, Salim S, Islam F (2003). Dosedependent protective effect of selenium in partial lesion model of Parkinson's disease: neurobehavioral and neurochemical evidences. J Neurochem 84:438-446. (Pubitemid 36182242)